Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sage Therapeutics' Stock Is Falling Today

By George Budwell – Mar 23, 2016 at 11:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech finds itself in the crosshairs of a noted short-seller.

What: Shares of Sage Therapeutics (SAGE 0.91%) fell by more than 20% in early morning trading Wednesday on heavy volume. The catalyst behind this downward move was a 28-page report issued by Kerrisdale Capital stating that the company's lead experimental product candidate SAGE-547 -- indicated for super-refractory status epilepticus (SRSE) -- is either likely to fail its ongoing late-stage trial, or turn out to be a commercial failure due to the presence of similar drugs on the market like benzodiazepines, anti-epileptics, and anesthetics that are already used to treat SRSE.

Image source: Creative Commons via Gerry Shaw. 

The firm also believes, according to the report, that Sage is overestimating the size of the drug's target market by perhaps a factor of 6, implying that SAGE-547 would, at best, be a minor drug from a revenue standpoint, if approved. 

SRSE is a rare, yet deadly, condition characterized by persistent seizures that fail to respond to standard forms of therapies. 

So what: Kerrisdale Capital thinks Sage's shares could drop by as much as 70% from current levels, given that the company's remaining clinical assets are mostly in the early stages of development. In short, Kerrisdale Capital is essentially valuing Sage at a little over its last stated cash position of around $186 million. 

Now what: Sage is expected to release top-line results from SAGE-547's late-stage trial in the second half of 2016, which will be the moment of truth for the biotech. While I don't have a crystal ball to predict the outcome of this particular clinical trial, the fact of the matter is that Sage's stock could very well crash if its lead product candidate misses the mark later this year. Unfortunately, that's a common theme among clinical-stage biotechs in general, and a big reason why I generally avoid these types of ultra-risky stocks. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sage Therapeutics Stock Quote
Sage Therapeutics
$37.79 (0.91%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.